PDF(1673 KB)
儿童pro-B急性淋巴细胞白血病的临床特点及预后分析
薛玉娟, 陆爱东, 王毓, 贾月萍, 左英熹, 张乐萍
中国当代儿科杂志 ›› 2020, Vol. 22 ›› Issue (12) : 1286-1294.
PDF(1673 KB)
PDF(1673 KB)
儿童pro-B急性淋巴细胞白血病的临床特点及预后分析
Clinical characteristics and prognostic analysis of pediatric pro-B cell acute lymphoblastic leukemia
目的 探究儿童pro-B急性淋巴细胞白血病（pro-B-ALL）的临床特点及预后影响因素。方法 回顾性选择64例年龄 < 18岁的pro-B-ALL患儿为研究对象，分析其临床特点、治疗和预后，以及生存率的影响因素。结果 pro-B-ALL患儿占儿童急性淋巴细胞白血病的6.23%（64/1 028）。64例患儿中男35例，女29例，中位确诊年龄7.0（范围0.4~16.0）岁，其中≥ 10岁和 < 1岁者分别占39%和6%，中位初诊白细胞计数25.5（范围0.4~831.9）×109/L，其中≥ 50×109/L者占35.9%。MLL-r阳性是最常见的分子遗传学异常（34%，22/64），常伴CD22、CD13低表达和CD7高表达，其中MLL-AF4阳性者常伴CD33低表达。64例患儿中位随访时间60.0（范围4.9~165.3）个月，5年总生存（OS）率及无事件生存（EFS）率分别为（85±5）%和（78±5）%。多因素分析显示，化疗3个月微小残留病≥ 0.1%是影响pro-B-ALL患儿5年OS率和EFS率的独立危险因素（P < 0.05）。结论 儿童pro-B-ALL具有独特的临床和生物学特征。初诊时的免疫抗原、分子遗传学异常及化疗3个月微小残留病水平是影响远期疗效的重要因素。
Objective To explore the clinical-biological characteristics and prognosis of pediatric pro-B cell acute lymphoblastic leukemia (pro-B-ALL). Methods A total of 64 patients aged less than 18 years old with pro-BALL were enrolled. Clinical characteristics, therapeutic effect and prognostic factors were retrospectively analyzed. Results Pro-B-ALL occurred in 6.23% (64/1 028) of pediatric ALL. Among the 64 patients, 35 were male and 29 were female. The median age was 7.0 years (range 0.4-16.0 years) at diagnosis, of which 39% and 6% were ≥ 10 years old and < 1 year old respectively. The median WBC count was 25.5×109/L[range (0.4-831.9)×109/L], of which 35.9% were ≥ 50×109/L. MLL-r positivity was the most frequent genetic alteration in pro-B ALL, occurring in 34% of patients, with lower frequency of CD22 and CD13 expression and higher frequency of CD7 expression, while lower frequency of CD33 expression was found in patients with MLL-AF4 positivity. At a median follow-up of 60.0 months (range 4.9-165.3 months), the estimated 5-year overall survival (OS) and event-free survival (EFS) in the 64 patients were (85±5)% and (78±5)% respectively. Cox proportional hazards regression analysis identified MRD ≥ 0.1% at 3 months after chemotherapy as an independent adverse prognostic factor for both 5-year OS and EFS. Conclusions Pediatric pro-B ALL is a heterogeneous disease with clinical and biological diversity. Biological characteristics, such as immunological markers, genetic alterations, and MRD at 3 months after chemotherapy may be important factors for the long-term prognosis.
急性淋巴细胞白血病 / pro-B细胞 / 生物学特征 / 预后 / 儿童
Acute lymphoblastic leukemia / pro-B cell / Biological characteristics / Prognosis / Child
[1] Gao C, Liu SG, Yue ZX, et al. Clinical-biological characteristics and treatment outcomes of pediatric pro-B ALL patients enrolled in BCH-2003 and CCLG-2008 protocol:a study of 121 Chinese children[J]. Cancer Cell Int, 2019, 19:293.
[2] Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)[J]. Leukemia, 1995, 9(10):1783-1786.
[3] Chen D, Gerasim?ik N, Camponeschi A, et al. CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemia[J]. Blood Cancer J, 2017, 7(6):e575.
[4] Pui CH, Rivera GK, Hancock ML, et al. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia[J]. Leukemia, 1993, 7(1):35-40.
[5] Winters AC, Bernt KM. MLL-rearranged leukemias-an update on science and clinical approaches[J]. Front Pediatr, 2017, 5:4.
[6] Campana D, Pui CH. Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia[J]. Blood, 2017, 129(14):1913-1918.
[7] Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008:the first nation-wide prospective multicenter study in China[J]. Am J Hematol, 2018, 93(7):913-920.
[8] 中华医学会儿科学分会血液学组, 中华儿科杂志编辑委员会. 儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J]. 中华儿科杂志, 2006, 44(5):392-395.
[9] 张之南. 血液病诊断及疗效标准[M]. 第2版. 北京:科学出版社, 1998:119-120.
[10] Attarbaschi A, Mann G, König M, et al. Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity[J]. Clin Cancer Res, 2006, 12(10):2988-2994.
[11] Dreyer ZE, Hilden JM, Jones TL, et al. Intensified chemotherapy without SCT in infant ALL:results from COG P9407(Cohort 3)[J]. Pediatr Blood Cancer, 2015, 62(3):419-426.
[12] Meyer C, Burmeister T, Gröger D, et al. The MLL recombinome of acute leukemias in 2017[J]. Leukemia, 2018, 32(2):273-284.
[13] Sun YN, Hu YX, Gao L, et al. The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol[J]. Eur Rev Med Pharmacol Sci, 2018, 22(18):6020-6029.
[14] Kato M, Hasegawa D, Koh K, et al. Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements:a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation[J]. Br J Haematol, 2015, 168(4):564-570.
[15] Bai L, Cheng YF, Lu AD, et al. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia[J]. Leuk Res, 2020, 91:106333.
[16] 陈晓娟, 邹尧, 刘晓明, 等. CCLG-ALL2008方案治疗不同分子生物学特征儿童急性淋巴细胞白血病的长期疗效分析[J]. 中国当代儿科杂志, 2019, 21(9):890-893.
[17] Jiang Z, Wu D, Lin S, et al. CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia[J]. Biomark Res, 2016, 4:23.
[18] Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia:analysis of 552 cases[J]. Leuk Lymphoma, 2011, 52(6):1098-1107.
[19] Li XM, Zhang LP, Wang YZ, et al. CD38+ CD58- is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients[J]. Leuk Res, 2016, 43:33-38.
[20] 卢业健, 邱兰兰, 王莉莉. CD58分子与急性淋巴细胞白血病和淋巴瘤相关性的研究进展[J]. 中国实验血液学杂志, 2017, 25(2):592-595.
[21] van Dongen JJ, van der Velden VH, Brüggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia:need for sensitive, fast, and standardized technologies[J]. Blood, 2015, 125(26):3996-4009.
[22] Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia:a meta-analysis[J]. JAMA Oncol, 2017, 3(7):e170580.
[23] Pui CH, Campana D. Minimal residual disease in pediatric ALL[J]. Oncotarget, 2017, 8(45):78251-78252.
2018年度北京市临床重点专科建设项目-儿科（2199000726）。
